智通财经APP讯,药明生物(02269)发布公告,有关涉及与爱尔兰疫苗设施相关的资产交易的须予披露交易。公司欣然宣布,根据协议条款,资产交易已于2025年3月31日落实交割。
根据协议,对价总额合共为4.996亿美元,当中包含:买方于交割时向卖方支付的4.07亿美元;买方于交割时向托管账户存入的3000万美元,以待于交割后十八个月届满时发放予卖方,惟倘卖方违反协议项下的任何保证或其他义务责任,则对价可因应买方提出的任何申索而有所下调;及余额以卖方先前从买方收取的经摊销预付款6263万美元(如卖方于该公告日期的最近可得财务报表所示)抵销。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.